Rocket Pharmaceuticals Rises After KRESLADI Approval Rocket Pharmaceuticals shares rose 22% on Mar 29, 2026 after FDA approval of KRESLADI; analysts project $250–$450m peak sales and a ~3,200 patient addressable market.

Rocket Pharmaceuticals Rises After KRESLADI Approval: Rocket Pharmaceuticals shares rose 22% on Mar 29, 2026 after FDA approval of KRESLADI; analysts project $250–$450m peak sales and a ~3,200 patient… 👈 Read full analysis #RocketPharmaceuticals #KRESLADI #FDAApproval #Pharmaceuticals #Biotech

Article image

Halozyme Therapeutics (HALO) appoints interim CFO as it prepares for growth. This could signal significant corporate developments ahead. #Biotech #CFO #HALO #ProfitPanic

Article image

Halozyme Therapeutics (HALO) nomina CFO ad interim mentre si prepara alla crescita. Questo potrebbe indicare importanti sviluppi aziendali in arrivo. #Biotech #CFO #HALO #AnalisiTecnopatica

Homepage - Confocal NL - Designed to respect your cells Discover the confocal systems that enable you to perform deep and fast live cell imaging, beyond the diffraction limit using only nanowatts of laser power.

🔬 confocalnl.com

#LiveCellImaging #Microscopy #Biotech #REscan #ZEN

Today: biotech opportunity at 65% prob. €80-140M val (median €110M), €10M min ticket.

DealPower keeps surfacing these profile-matched signals weekly.

Demo? Reply 'DEMO' or DM.
What's your focus right now ? Startups ? rare Assets ? or Art? Or anything else ? 👀
#UHNW #Biotech #VentureCapital

✨ Thrilled to welcome Vera Meyer (TU Berlin) as a #PYFF9 speaker!
🧬 A leader in #fungal #genetics, #biotechnology & #molecular #microbiology.
Don’t miss her talk! 🚀
#Biotech #FungalScience
Join us in Valencia! 🇪🇸

#Valencia2026

The bigger takeaway: biopharma is rewarding assets that are differentiated, scalable, and defensible on evidence.

Follow me for weekly updates on the biotech, pharma, and healthcare developments worth actually paying attention to. #Biotech #Healthcare

Biopharma this week in one view:

#Biotech #Pharma #Healthcare

#News: Can #yeast save the #rainforests? 🧐🍄 Scientists create "designer enzyme" turning yeast into a #palmoil or #coconut oil alternative! 🛑🌴 🧪✨ #BioTech #BoycottPalmOil #Boycott4Wildlife @palmoildetect.bsky.social https://www.geneonline.com/designer-enzyme-enables-yeast-to-produce-fatty-acids-as-sustainable-alternatives-to-palm-and-coconut-oil/

#News: Can #yeast save the #rainforests? 🧐🍄 Scientists create "designer enzyme" turning yeast into a #palmoil or #coconut oil alternative! 🛑🌴 🧪✨ #BioTech #BoycottPalmOil #Boycott4Wildlife @palmoildetect.bsky.social www.geneonline.com/designer-enz...

We are now on @bsky.app
#Bioeconomy
#Sustainability
#Biorevolution
#Biotech
#Green
#Growth
#Circular

MultiSearch Tag Explorer MultiSearch Tag Explorer - Explore tags and search results by aéPiot - aéPiot: Independent SEMANTIC Web 4.0 Infrastructure (Est. 2009). High-density Functional Semantic Connectivity with 100/100 Trust...

#INTERNATIONAL #SERVICE #FOR #THE #ACQUISITION OF #AGRI #BIOTECH #APPLICATIONS
aepiot.ro/advanced-sea...
2026 IN #BRITISH #RADIO
headlines-world.com/advanced-sea...
#WORLD #WAR II IN #POPULAR #CULTURE
multi-search-tag-explorer.headlines-world.com/advanced-sea...
aepiot.com

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops | #biotech #pharma

RobinReach

🚨 WARNING: Your Bandage Is Alive. Dare to discover living bandages that sense and adapt to reimagine first aid. Watch now: https://youtu.be/AsGdeWWh4N4 🩹🧬▶️
#Biotech #HealthTech #Innovation #Science

A black-and-white cartoon with red accents shows a lab scene transitioning away from animal testing: a rabbit and mouse sit by an open cage door, appearing cautiously hopeful, while nearby glass jars display small, stylized human organs glowing faintly. In the center, two suited officials carry folders as they move toward a modern lab filled with robotic arms, microscopes, and researchers analyzing organ-like structures and data. In the foreground, scientists work at computers and lab benches, surrounded by interconnected devices and samples, suggesting a coordinated, high-tech research system replacing older methods.

FDA + NIH are pushing non-animal research into the mainstream. New FDA guidance opens flexibility for NAMs, while NIH backs it with $150M for tech centers + data hubs. It’s shifting from ethics talk to real infrastructure for human-relevant science. #biotech scientificinquirer.com/2026/03/25/d...

China's Hemophilia A Gene Therapy Partnership That Could Change Everything - AktieGo Belief BioMed and Grand Life Sciences partner to bring BBM-H803 gene therapy to 30,000 hemophilia A patients in China. Here's what it means for treatment access.

China is rewriting the rules for hemophilia treatment.
Exclusive partnership pushes cutting-edge gene therapy forward. Hope for thousands of patients just got real.
Don’t miss this biotech breakthrough →
aktiego.com/sectors/biot...
#GeneTherapy #Biotech #HemophiliaA #ChinaInnovation #Science

Gene & Cell Therapy and Rare Disease Intelligence - LucidQuest Strategic insights for gene and cell therapy from R&D through commercialization. Primary KOL research, competitive analysis, and investment diligence in rare diseases.

🧬 Gene & Cell Therapy | #RareDiseases 🚀
#LucidQuest delivers sharp insights to help biotechs, investors & BD teams stay ahead in fast-moving markets.
📩 info@lqventures.com or http://dlvr.it/TRlGZt
#GeneTherapy #CellTherapy #Biotech #DueDiligence #InvestmentInsights

Anaptysbio CEO Sells $1.1M in Shares Anaptysbio CEO Faga sold $1.1M of ANAB stock on Mar 27, 2026 (Investing.com); institutional investors should verify SEC Form 4 and assess ownership impact.

Anaptysbio CEO Sells $1.1M in Shares: Anaptysbio CEO Faga sold $1.1M of ANAB stock on Mar 27, 2026 (Investing.com); institutional investors should verify SEC Form 4 and assess ownership impact. 👈 Read full analysis #Anaptysbio #CEO #StockMarket #Investing #Biotech

Norgen Biotek’s Director of Global Sales & Marketing, Dr. Bernard Kim, will be speaking with Lab2Market about turning academic research into scalable biotech innovation.

Register here: luma.com/uf4qv3ju
#Biotech #Innovation

Autolus Reiterates $120M–$135M AUCATZYL 2026 Target Autolus reiterated a $120M–$135M 2026 revenue target for AUCATZYL on Mar. 27, 2026 and said it will expand its pivotal-trial program (Seeking Alpha).

Autolus Reiterates $120M–$135M AUCATZYL 2026 Target: Autolus reiterated a $120M–$135M 2026 revenue target for AUCATZYL on Mar. 27, 2026 and said it will expand its pivotal-trial program (Seeking Alpha). 👈 Read full analysis #Autolus #AUCATZYL #Biotech #Pharmaceuticals #ClinicalTrials

PlaneAlert ICAO: A6FF7F Tail: N550AV Flt: N550AV
Owner: AbbvieUS
Aircraft: Gulfstream G550
2026-03-27 10:41:17 CDT
GLF5 Civ Bizjet Biotech Pharmaceuticals AsSeenonTV
- wiki - adsbexchange

Agilent aria mx real time pcr

$7495 with promo code! Save $1000 when you call and use the promo code REALTIME 10!  Deal Ends Tuesday, March 31st
#LabEquipment #MidMonthSale #LabDeals #ScienceSavings #LabLife #Biotech #Pharma #ResearchLab #LabUpgrade #ScientificEquipment #LabWorld #ScienceTools

Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Up and Down the Ladder: Job Changes... the latest comings and goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs

ORIC Pharmaceuticals to Report Prostate Trial Data Tuesday ORIC (NASDAQ: ORIC) will publish prostate cancer cohort data on Tuesday, Mar 31, 2026 (Investing.com); this binary readout could move valuation by ±25% or more.

ORIC Pharmaceuticals to Report Prostate Trial Data Tuesday: ORIC (NASDAQ: ORIC) will publish prostate cancer cohort data on Tuesday, Mar 31, 2026 (Investing.com); this binary readout could move valuation by ±25% or… 👈 Read full analysis #ORIC #ProstateCancer #Biotech #ClinicalTrials #Pharmaceuticals

Immix Biopharma Target Raised to $15 H.C. Wainwright raised Immix Biopharma's price target to $15 on Mar 27, 2026, signaling revised valuation assumptions; institutional investors should triangulate with SEC filings.

Immix Biopharma Target Raised to $15: H.C. Wainwright raised Immix Biopharma's price target to $15 on Mar 27, 2026, signaling revised valuation assumptions; institutional investors should triangulate with SEC… 👈 Read full analysis #ImmixBiopharma #Hcwainwright #PriceTarget #Investing #Biotech

PlaneAlert ICAO: A6FF7F Tail: N550AV
Owner: AbbvieUS
Aircraft: Gulfstream G550
2026-03-27 07:42:38 EDT
GLF5 Bizjet Biotech Pharmaceuticals AsSeenonTV
adsb - wiki - adsbexchange

Combined company targets mitochondrial biology and body composition as longevity biotech edges into mainstream markets

Link as first comment.

#longevity #geroscience #biotech #healthspan

RobinReach

Shocking. An Army radar tech’s hip implant beats on its own. Gear up to chase the why and explore the unknown. Watch now 👉 https://youtu.be/rWRxhRWQtUQ 🔍⚡ #TechMystery #MilitaryTech #BioTech #StayCurious

📢 #YsiosNews I #InceptionBio, a €100M target fund to drive #biotech #companycreation and #earlystage innovation, with a strong focus on #Spain

🔹First closing completed with CDTI Innovacion
🔹Target 3 new biotech companies in 2026

👉 buff.ly/evaem36

#vc #techtransfer

1 Week Left to Register! Expand your expertise in #MedPubs and #MedComms at this year's Annual Meeting! Check out the full agenda and register by April 3 buff.ly/WDuaxuJ

#ISMPPAnnual #AI #BioTech

Magnetic Beads Market Size & Share | Industry Report 2035 The Magnetic Beads Market is projected to grow from USD 3.58 Billion in 2024 to USD 12.34 Billion by 2035 at 11.90% CAGR.

The Magnetic Beads Market is on the move! 📈 Valued at $3.58B in 2024, it's set to hit $12.34B by 2035 (11.9% CAGR). 🚀

Key drivers: Bioresearch & In-vitro Diagnostics. 🛠️🦾

Report: www.marketresearchfuture.com/reports/magn...

#Biotech #Diagnostics #LifeSciences #MarketResearch